FG-2101: a First-In-Class Lpxc Inhibitor for the Treatment of MDR Gramnegative Urinary Tract Infections

Contract Overview

Contract Amount: $12,132,070 ($12.1M)

Contractor: Blacksmith Medicines, Inc.

Awarding Agency: Department of Health and Human Services

Start Date: 2022-09-21

End Date: 2026-12-31

Official Description: FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS.